The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 230 patients with chronic respiratory tract infection or pneumonia in the well controlled study at 33 institutions in Japan. Patients were given daily ceftizoxime 2 g or cefazolin 4 g by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference in therapeutic efficacy was observed between the patients with respiratory tract infection given ceftizoxime 2 g/day and cefazolin 4 g/day. 2) The therapeutic efficacy of ceftizoxime 2 g/day was significantly superior to that of cefazolin 4 g/day except in patients with elevated mycoplasmal antibody and/or cold hemagglutinin titer. 3) The improvement in sputum volume of patients with pneumonia or lung abscess was significantly better in the cefazolin group than in the ceftizoxime group on the 3 rd day of dosing and in patients with respiratory tract infection except pneumonia and lung abscess, on the 14 th day of dosing. 4) The eradication rate of causative organisms isolated from patients was significantly higher in the ceftizoxime group than in the cefazolin group. 5) No significant difference was noted between the two drug groups in incidence of adverse reactions. These findings suggest that the therapeutic efficacy of ceftizoxime 2 g/day on bacterial respiratory tract infection is more excellent than that of cefazolin 4 g/day.
ASJC Scopus subject areas